Table 4.
Univariate Progression-free survival
| Variable | Median PFS (95% CI) | HR (95% CI) | p-value |
|---|---|---|---|
| All | 23.2 (17.4–39.7) | ||
| Age | 1.02 (1–1.05) | 0.069 | |
| BMI | 1.01 (0.97–1.05) | 0.654 | |
| SLN Group | |||
| SLN | 23 (17.5-NE) | 1 | 0.706 |
| Non-SLN | 23.2 (15.5–41.8) | 1.1 (0.66–1.83) | |
| Stage | |||
| I/II | 53.2 (21.2-NE) | 1 | <0.001 |
| III | 24.5 (8.8–72) | 1.49 (0.83–2.67) | |
| IV | 10.1 (4.6–13) | 4.4 (2.51–7.73) | |
| Invasion | |||
| <50% | 53.2 (22.7-NE) | 1 | <0.001 |
| >50% | 11.2 (8.1–17.7) | 2.57 (1.62–4.07) | |
| LVSI | |||
| Yes | 17.4 (11.9–23.2) | 1 | 0.021 |
| No | 41.8 (21.6-NE) | 0.59 (0.37–0.93) | |
| Adjuvant Therapy | 0.417 | ||
| Any chemotherapy | 26.5 (17.9–96.8) | 1 | |
| Radiation therapy | 14.6 (9–26.6) | 1.52 (0.81–2.86) | |
| None | 37.9 (0.2-NE) | 1.1 (0.44–2.76) |
Abbreviations: SLN = sentinel lymph node. LVSI = lymphovascular space invasion. CT = chemotherapy. RT = radiation therapy. PFS = progression free survival. HR = hazard ratio. NE = not estimable.
*
landmark analysis: 8 weeks postoperative